CTC
NBIX icon

Central Trust Company’s Neurocrine Biosciences NBIX Stock Holding History

Central Trust Company’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.07K Sell
36
-2
-5% -$297 ﹤0.01% 1299
2026
Q1 		$5.01K Hold
38
– – ﹤0.01% 1255
2025
Q4 		$5.39K Buy
38
+2
+6% +$290 ﹤0.01% 1211
2025
Q3 		$5.05K Hold
36
– – ﹤0.01% 1198
2025
Q2 		$4.53K Sell
36
-40
-53% -$4.59K ﹤0.01% 1226
2025
Q1 		$8.41K Sell
76
-10
-12% -$1.27K ﹤0.01% 1138
2024
Q4 		$11.7K Buy
86
+10
+13% +$1.24K ﹤0.01% 1073
2024
Q3 		$8.76K Hold
76
– – ﹤0.01% 1084
2024
Q2 		$10.5K Hold
76
– – ﹤0.01% 1059
2024
Q1 		$10.5K Hold
76
– – ﹤0.01% 1073
2023
Q4 		$10K Sell
76
-60
-44% -$6.91K ﹤0.01% 1075
2023
Q3 		$15.3K Buy
136
+36
+36% +$3.79K ﹤0.01% 974
2023
Q2 		$9.43K Sell
100
-245
-71% -$23.9K ﹤0.01% 1036
2023
Q1 		$34.9K Sell
345
-62
-15% -$6.45K ﹤0.01% 852
2022
Q4 		$48.6K Sell
407
-15
-4% -$1.76K ﹤0.01% 773
2022
Q3 		$45K Buy
+422
New +$42.8K ﹤0.01% 789
2020
Q3 		– Sell
-250
Closed -$31K – 1092
2020
Q2 		$31K Hold
250
– – ﹤0.01% 694
2020
Q1 		$22K Hold
250
– – ﹤0.01% 742
2019
Q4 		$27K Hold
250
– – ﹤0.01% 775
2019
Q3 		$23K Buy
+250
New +$23.4K ﹤0.01% 774

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Central Trust Company's NBIX Position: Q2 2026 in Review

Central Trust Company reduced its Neurocrine Biosciences (NBIX) stake by 5.3% in Q2 2026, selling an estimated $297 and leaving 36 shares worth $6.07K. The position accounts for ﹤0.01% of the portfolio, ranked #1299.

Central Trust Company first reported a position in NBIX in Q3 2019 and has held it in 20 quarters since. The position peaked at $48.6K in Q4 2022. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Central Trust Company held 36 shares of Neurocrine Biosciences worth $6.07K as of Q2 2026.
  • Central Trust Company sold 2 Neurocrine Biosciences shares in Q2 2026, an estimated $297.
  • Neurocrine Biosciences made up ﹤0.01% of Central Trust Company's portfolio in Q2 2026, its #1299 holding.
  • Central Trust Company first reported a position in Neurocrine Biosciences in Q3 2019 and has held it in 20 quarters since.
  • Central Trust Company's Neurocrine Biosciences position peaked at $48.6K in Q4 2022.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Central Trust Company's 13F filing for Q2 2026, filed 31 Jul 2026.